NCT04284488 - Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors | Biotech Hunter

Enrollment

104

Participants

Timeline

Start Date

April 10, 2020

Primary Completion Date

April 30, 2024

Study Completion Date

April 30, 2024

Conditions

Advanced Solid Tumor

Interventions

DRUG

APG-1387 for Injection

APG-1387 IV on Days 1 and 8 of each 21-Day Cycle. The following doses of APG-1387 to be studied: 20, 30, and 45mg. In the phase II, the assigned recommended phase two dose will be administered in all cohorts.

DRUG

Toripalimab

240 mg toripalimab IV on Day 1 of each 21-Day Cycle

Trial Locations (3)

510060

RECRUITING

Sun-Yat Sen University Cancer Center, Guangzhou

530021

NOT_YET_RECRUITING

The Affiliated Hospital OF Guangxi Medical University, Nanning

Unknown

RECRUITING

Foshan First People's Hospital, Foshan